This high phosphorylation capability of mutant BRaf, when couples with the mutant P16/INK4a as the result of cyclin-dependent kinase inhibitor 2A (CDKN2A) mutation or phosphatase and tensin homolog (PTEN) mutation, can lead to melanoma development (17, 18). The gene discussed is BRAF; the disease is melanoma.